Overview

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Bimatoprost
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Travoprost